Literature DB >> 24837361

New oral anticoagulants (NOAC) and liver injury.

Nicholas Moore1, Patrick Blin2, Sinem-Ezgi Gulmez2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24837361     DOI： 10.1016/j.jhep.2014.05.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  3 in total

1.  Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Ariola Koci; Francesco Salvo; Antoine Pariente; Maurizio Biselli; Ugo Moretti; Nicholas Moore; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2015-05-20       Impact factor: 4.335

Review 2.  Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.

Authors:  Emanuel Raschi; Fabrizio De Ponti
Journal:  World J Hepatol       Date:  2015-07-08

3.  Non-hemorrhage-related adverse effects of rivaroxaban.

Authors:  Eliza C Christopoulou; Theodosios D Filippatos; Moses S Elisaf
Journal:  Arch Med Sci Atheroscler Dis       Date:  2017-12-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.